MedTrace Logo

Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic

NCT04387292 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2026-01-06

No results posted yet for this study

Summary

Ophthalmologic damages secondary to COVID-19 coronavirus infection are little described. The ocular involvement is probably multiple, ranging from pathologies of the anterior segment such as conjunctivitis and anterior uveitis to disorders that threaten vision such as retinitis or optic neuropathy. On the other hand, in addition to this impairment, when patients are hospitalized for acute respiratory failure, complications related to possible resuscitation, medication prescriptions, positioning and oxygenation.

COVID-19 itself, has several components:

* An apoptotic action of the viral attack which will generate cellular destruction, whether pulmonary, cardiac or renal or maybe ocular
* A secondary autoimmune action with the development of major vascular inflammation, possibly reaching the retinal, choroidal, and optic nerve vessels. A secondary "hyper" inflammatory syndrome with flashing hypercytokinemia and multi-organ decompensation is described in 3,7% to 4 ,3% of severe cases.
* A thromboembolic action

Conditions

  • COVID19
  • Ophthalmopathy

Interventions

PROCEDURE

Ophthalmologic exam

* Visual acuity (ETDRS exam) * Slit lamp examination : fluorescein test, Oxford score, break up time, Schirmer II test * Lipiview * Eye pressure measurement (air tonometer) * Wide field retinophotography * Multicolor and auto-fluorescence retinophotography * Indocyanine green retinal angiography * Optical coherence tomography (OCT) B posterior pole scan * OCT Angiography (OCT-A) of the optic nerve and posterior pole * Adaptive optics * Visual field (Humphrey)

Sponsors & Collaborators

  • Fondation Ophtalmologique Adolphe de Rothschild

    lead NETWORK

Principal Investigators

  • Martine MAUGET FAYSSE, MD · Fondation A. de Rothschild

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-07
Primary Completion
2021-01-21
Completion
2021-05-15

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04387292 on ClinicalTrials.gov